Paul Tudor Jones’s Acorda Therapeutics ACOR Stock Holding History

Paul Tudor Jones’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-559	Closed	-$193K	–	1437
2019 Q3	$193K	Buy	+559	New	+$304K	0.01%	963
2019 Q2	–	Sell	-129	Closed	-$206K	–	1403
2019 Q1	$206K	Sell	129 -449	-78%	-$809K	0.01%	996
2018 Q4	$1.08M	Buy	+578	New	+$1.26M	0.02%	357
2018 Q3	–	Sell	-63	Closed	-$217K	–	1318
2018 Q2	$217K	Buy	+63	New	+$193K	0.01%	903
2018 Q1	–	Sell	-141	Closed	-$362K	–	1314
2017 Q4	$362K	Buy	+141	New	+$401K	0.01%	737
2017 Q2	–	Sell	-103	Closed	-$260K	–	1453
2017 Q1	$260K	Sell	103 -84	-45%	-$242K	0.01%	1086
2016 Q4	$421K	Buy	+187	New	+$445K	0.01%	812
2016 Q3	–	Sell	-113	Closed	-$345K	–	1803
2016 Q2	$345K	Sell	113 -92	-45%	-$299K	0.01%	1078
2016 Q1	$651K	Buy	+205	New	+$851K	0.02%	781
2015 Q2	–	Sell	-118	Closed	-$473K	–	1726
2015 Q1	$473K	Buy	+118	New	+$540K	0.02%	765
2014 Q1	–	Sell	-142	Closed	-$496K	–	1449
2013 Q4	$496K	Buy	142 +78	+122%	+$304K	0.02%	561
2013 Q3	$263K	Buy	64 +2	+3%	+$8.62K	0.01%	645
2013 Q2	$244K	Buy	+62	New	+$255K	0.02%	651

Other funds holding ACOR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Paul Tudor Jones's ACOR Position: Q4 2019 in Review

Paul Tudor Jones sold out of Acorda Therapeutics (ACOR) in Q4 2019, closing a stake of 559 shares — an estimated $193K sold.

Paul Tudor Jones first reported a position in ACOR in Q2 2013 and held it in 13 quarters. The position peaked at $1.08M in Q4 2018. 121 funds tracked by Wall St. Rank hold ACOR as of Q4 2019.

Paul Tudor Jones reported no remaining Acorda Therapeutics position as of Q4 2019 after selling out during the quarter.
Paul Tudor Jones sold 559 Acorda Therapeutics shares in Q4 2019, an estimated $193K.
Paul Tudor Jones first reported a position in Acorda Therapeutics in Q2 2013 and held it in 13 quarters.
Paul Tudor Jones's Acorda Therapeutics position peaked at $1.08M in Q4 2018.
121 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2019.

Based on Tudor Investment Corp's 13F filing for Q4 2019, filed 14 Feb 2020.